Stoke Therapeutics Q3 net loss $26.4M; FDA lifts partial clinical hold on zorevunersen; STK-002 Phase 1 delayed

Stoke Therapeutics, Inc.

2024-Q3 EPS reported -$1.48 revenue$13,941,000

Cash, equivalents, and marketable securities $269.2M as of Sep 30, 2024.
Net loss Q3 2024 $26.4M ($0.47/shr) vs $24.5M ($0.55/shr) Q3 2023.
Revenue from Acadia collaboration $4.9M in Q3 2024 vs $3.3M in Q3 2023.
FDA removed partial clinical hold on zorevunersen; plans to provide Phase 3 data and regulatory update by year-end.
Phase 1 study of STK-002 (ADOA) delayed to focus on zorevunersen.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.